Amgen (NASDAQ: AMGN) is a top drugmaker whose shares have risen by more than 70% in five years, which is a bit shy of the S 500's 90% gain over that stretch. With some promising products in its pipeline, the future does looks encouraging. However, some investors might be concerned about the company's high debt load.

Here's where the business might go from here, and whether it's worth investing in Amgen today.

The biggest product Amgen investors should be excited about is MariTide, a weight loss drug that could prove to be a thorn in the sides of both Novo Nordisk and Eli Lilly.

Continue reading

Source Fool.com